Renal clearance of endogenous hippurate correlates with expression levels of renal organic anion transporters in uremic rats

被引:66
作者
Deguchi, T
Takemoto, M
Uehara, N
Lindup, WE
Suenaga, A
Otagiri, M
机构
[1] Kumamoto Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, Kumamoto 8620973, Japan
[2] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England
关键词
D O I
10.1124/jpet.105.085613
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hippurate ( HA) is a harmful uremic toxin that accumulates during chronic renal failure, and failure of the excretion system for uremic toxins is thought to be responsible. Recently, we reported that rat organic anion transporter 1 (rOat1) is the primary mediator of HA uptake in the kidney, and so now we have studied the pharmacokinetics and tissue distribution of HA after a single i.v. dose of HA to normal and 5/6 nephrectomized rats (5/6Nx rats). In control rats, the renal and biliary clearances of HA were 18.1 and 0.1 ml/min/kg, respectively. Plasma clearance decreased as dosage increased from 0.1 to 5 mg/kg, which suggests that renal tubular secretion is the primary route for elimination of HA. The plasma clearance of HA was significantly decreased in 5/6 Nx rats compared with normal rats. In 5/6 Nx rats, renal clearance of endogenous HA correlated more closely with clearance of p-aminohippurate than with that of creatinine. Protein expression of rOat1 and rOat3, assessed by Western blot analysis, was decreased in 5/6 Nx rats. Furthermore, in 5/6 Nx rats, the renal secretory clearance of endogenous HA correlated closely with protein expression of renal rOats. Thus, HA is primarily eliminated from the plasma via the kidney by active tubular secretion. The renal clearance of endogenous HA seems to be a useful indicator of changes in renal secretion that accompany the reduced levels of OAT protein in chronic renal failure.
引用
收藏
页码:932 / 938
页数:7
相关论文
共 40 条
[1]   Effects of oral adsorbent on gene expression profile in uremic rat kidney: cDNA array analysis [J].
Aoyama, I ;
Enomoto, A ;
Niwa, T .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (03) :S8-S14
[2]   URICOSURIC AGENTS IN UREMIC SERA - IDENTIFICATION OF INDOXYL SULFATE AND HIPPURIC ACID [J].
BOUMENDILPODEVIN, EF ;
PODEVIN, RA ;
RICHET, G .
JOURNAL OF CLINICAL INVESTIGATION, 1975, 55 (06) :1142-1152
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]   Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney [J].
Cha, SH ;
Sekine, T ;
Fukushima, J ;
Kanai, Y ;
Kobayashi, Y ;
Goya, T ;
Endou, H .
MOLECULAR PHARMACOLOGY, 2001, 59 (05) :1277-1286
[5]  
Costigan MG, 1996, NEPHRON, V73, P169
[6]   Characterization of uremic toxin transport by organic anion transporters in the kidney [J].
Deguchi, T ;
Kusuhara, H ;
Takadate, A ;
Endou, H ;
Otagiri, M ;
Sugiyama, Y .
KIDNEY INTERNATIONAL, 2004, 65 (01) :162-174
[7]   Pharmacokinetics and tissue distribution of uraemic indoxyl sulphate in rats [J].
Deguchi, T ;
Nakamura, M ;
Tsutsumi, Y ;
Suenaga, A ;
Otagiri, M .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2003, 24 (08) :345-355
[8]  
Dzúrik R, 2001, KIDNEY INT, V59, pS278
[9]   Interactions of human organic anion as well as cation transporters with indoxyl sulfate [J].
Enomoto, A ;
Takeda, M ;
Taki, K ;
Takayama, F ;
Noshiro, R ;
Niwa, T ;
Endou, H .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 466 (1-2) :13-20
[10]   Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors [J].
Enomoto, A ;
Takeda, M ;
Shimoda, M ;
Narikawa, S ;
Kobayashi, Y ;
Kobayashi, Y ;
Yamamoto, T ;
Sekine, T ;
Cha, SH ;
Niwa, T ;
Endou, H .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (03) :797-802